| 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | 港元） | （港元） | （港元） | （万港元） | | 00700 | 腾讯控股 | 97.50 | 50084.93 | 516.500 | 511.500 | 2853315.68 | | 01299 | 友邦保险 | 300.00 | 20382.49 | 69.000 | 67.150 | 1206539.55 | | 00670 | 中国东方航 空股份 | 220.00 | 648.42 | 2.970 | 2.920 | 49816.45 | | 01519 | 极兔速递-W | 92.00 | 626.52 | 6.870 | 6.730 | 25362.34 | | 09987 | 百胜中国 | 1.39 | 467.34 | 339.400 | 335.200 | 70033.89 | | 01907 | 中国旭阳集 团 | 165.00 | 412.92 | 2.5 ...

6月3日港股公司回购一览 腾讯控股回购数量99.40万股，回购金额5.00亿港元，回购最高价为505.000港元，最低价为501.000港 元，年内累计回购金额270.31亿港元；友邦保险回购数量600.00万股，回购金额4.03亿港元，回购最高 价为67.650港元，最低价为66.550港元，年内累计回购金额114.12亿港元；快手-W回购数量200.00万 股，回购金额1.02亿港元，回购最高价为51.350港元，最低价为50.950港元，年内累计回购金额19.11亿 港元。 以金额进行统计，6月3日回购金额最多的是腾讯控股，回购金额为5.00亿港元；其次是友邦保险，回购 金额为4.03亿港元；回购金额居前的还有快手-W、恒安国际等。回购数量上看，6月3日回购股数最多 的是友邦保险，当日回购量为600.00万股；其次是中远海发、有赞等，回购数量分别为462.70万股、 200.00万股。 值得关注的是，非凡领越本次回购为年内首次进行回购。本次回购5.00亿港元的腾讯控股，年内则进行 多次回购，合计回购金额为270.31亿港元。（数据宝） 证券时报·数据宝统计显示，6月3日有40家香港上市公司进行了股份回购 ...

| 思派健康(00314) | 5.00 万 | 18.72 万 | 1383.92 万 | 1.815% | | --- | --- | --- | --- | --- | | 中国有赞(08083) | 200.00 万 | 18.20 万 | 1920.00 万 | 0.059% | | 骏杰集团控股(08188) | 10.00 万 | 8.40 万 | 20.00 万 | 0.042% | | 滨海投资(02886) | 5.60 万 | 5.66 万 | 31.20 万 | 0.023% | | 玄武云(02392) | 2.90 万 | 2.62 万 | 339.05 万 | 0.605% | | 天福(06868) | 3000.00 | 9530.00 | 17.30 万 | 0.016% | | 清科创业(01945) | 3600.00 | 5300.00 | 10.92 万 | 0.036% | | 彩客新能源(01986) | 7000.00 | 4910.00 | 27.90 万 | 0.029% | | 华检医疗(01931) | 2000.00 | 4260.00 | 182. ...

Summary of Key Points Core Viewpoint - On May 27, 36 Hong Kong-listed companies conducted share buybacks totaling 25.22 million shares, with a total buyback amount of 1.047 billion HKD [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 979,000 shares for 500 million HKD, with a highest price of 514.000 HKD and a lowest price of 507.000 HKD, bringing its total buyback amount for the year to 24.53 billion HKD [1][2]. - Meituan-W repurchased 3.02 million shares for 392 million HKD, with a highest price of 132.400 HKD and a lowest price of 122.600 HKD, totaling 392 million HKD in buybacks for the year [1][2]. - China COSCO Shipping repurchased 6.17 million shares for 89.84 million HKD, with a highest price of 14.820 HKD and a lowest price of 14.280 HKD, accumulating 4.41 billion HKD in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on May 27 was from Tencent Holdings at 500 million HKD, followed by Meituan-W at 392 million HKD [1][2]. - In terms of buyback volume, China COSCO Shipping led with 6.17 million shares, followed by NetEase Technology and Meituan-W with 5 million shares and 3.02 million shares, respectively [1][2]. Group 3: First-Time Buybacks - Notably, Meituan-W and Zhongxu Future conducted their first buybacks of the year on this date [2].

Summary of Key Points Core Viewpoint - On May 19, 38 Hong Kong-listed companies conducted share buybacks, totaling 38.39 million shares and an aggregate amount of HKD 831 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 979,000 shares for HKD 500 million, with a highest price of HKD 516.50 and a lowest price of HKD 503.00, bringing its total buyback amount for the year to HKD 21.53 billion [1][2]. - AIA Group repurchased 2.34 million shares for HKD 154 million, with a highest price of HKD 66.40 and a lowest price of HKD 64.75, totaling HKD 8.93 billion in buybacks for the year [1][2]. - China COSCO Shipping repurchased 5.56 million shares for HKD 79.36 million, with a highest price of HKD 14.40 and a lowest price of HKD 14.12, accumulating HKD 3.83 billion in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on May 19 was from Tencent Holdings at HKD 500 million, followed by AIA Group at HKD 154 million [1][2]. - In terms of share quantity, the largest buyback was conducted by Jieli Trading at 9.18 million shares, followed by China COSCO Shipping at 5.56 million shares and NetEase Technology at 4.67 million shares [1][2]. Group 3: Additional Buyback Information - Country Garden Services conducted its first buyback of the year, while Tencent Holdings has made multiple buybacks totaling HKD 21.53 billion [2][3]. - A detailed table of buybacks on May 19 includes various companies, their respective buyback shares, amounts, highest and lowest prices, and cumulative buyback amounts for the year [2][3].

Summary of Key Points Core Viewpoint - On May 13, 39 Hong Kong-listed companies conducted share buybacks, totaling 24.76 million shares and an amount of 321 million HKD [1][2]. Group 1: Share Buyback Details - AIA Group repurchased 3.72 million shares for 231.19 million HKD, with a highest price of 63.20 HKD and a lowest price of 61.75 HKD, accumulating a total buyback amount of 8.44 billion HKD for the year [1][2]. - Times Electric repurchased 750,700 shares for 24.87 million HKD, with a highest price of 33.20 HKD and a lowest price of 32.85 HKD, totaling 1.23 billion HKD in buybacks for the year [1][2]. - Swire Pacific A repurchased 300,000 shares for 20.97 million HKD, with a highest price of 70.00 HKD and a lowest price of 69.60 HKD, accumulating 1.66 billion HKD in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on May 13 was from AIA Group at 231.19 million HKD, followed by Times Electric at 24.87 million HKD [1][2]. - In terms of share quantity, the largest buyback was from COSCO Shipping Development with 5 million shares, followed by Ying Group and AIA Group with 4 million shares and 3.72 million shares respectively [1][2].

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has successfully removed the "B" mark from its stock code, becoming the first 18A high-value consumable medical device company in Hong Kong to achieve this milestone, indicating its growth and profitability recognition by the capital market [3][4]. Financial Performance - In 2024, Guichuang Tongqiao achieved a revenue of 780 million RMB, representing a year-on-year growth of 48.3% [4][8]. - The net profit for the year surpassed 100 million RMB, marking the company's first annual profit [4][8]. - The gross profit margin was recorded at 71.6%, slightly down from the previous year due to price reductions from centralized procurement and proactive pricing strategies to gain market share [8]. - The net cash flow from operating activities reached 174 million RMB, an increase of 76.83% year-on-year [8]. Product Development and Market Position - The company has continuously invested in R&D, leading to successful bids for core products in multiple provincial and national procurement rounds in 2024 [4]. - Key products include the Tongqiao Silver Snake intracranial support catheter and ZYLOX Penguin iliac vein stent, which have gained significant market traction [4][9]. - Guichuang Tongqiao focuses on peripheral vascular intervention and neurointervention consumables, with leading products in the treatment of lower limb artery occlusive disease and deep vein thrombosis [9]. Industry Landscape - The 18A high-value consumables sector in Hong Kong has become increasingly competitive since the first listing of a medical device company under this category in December 2019 [7]. - Companies like Xianruida Medical and Peijia Medical are also emerging in this space, focusing on differentiated competition in peripheral vascular, neurointervention, and heart valve segments [7][9]. - The market is characterized by rapid technological advancements and commercialization efforts, with several companies achieving profitability and significant revenue growth [7][9]. Company Overview - Established in 2012, Guichuang Tongqiao specializes in the R&D, production, and sales of neurovascular and peripheral vascular intervention medical devices [10]. - The company aims to provide high-quality and affordable treatment solutions for cardiovascular disease patients through innovative medical device products [10]. - As of now, Guichuang Tongqiao has developed a product pipeline of 66 items, with 47 products approved for market release by NMPA, and its marketing network covers over 3,000 hospitals in China [10].

Group 1 - The article reports on share buybacks conducted by various companies on May 12, 2025, with AIA Group (01299) having the largest buyback amount of 1.25 billion, purchasing 2 million shares [1][2] - Other notable buybacks include China COSCO Shipping Holdings (01919) with 4.21 million shares bought back for 53.77 million, and Times Electric (03898) with 1.43 million shares for 47.22 million [2][3] - The total number of shares repurchased by AIA Group in the year reached 5.93 billion, accounting for 5.276% of its total share capital [2] Group 2 - China Hongqiao Group (01378) repurchased 1.13 million shares for 15.96 million, representing only 0.380% of its total share capital [2] - Swire Properties (00019) bought back 181,000 shares for 12.67 million, with a total annual repurchase of 5.56 million shares, which is 6.652% of its total [2] - The buyback activity reflects a trend among companies to utilize excess cash for share repurchases, potentially signaling confidence in their financial health [1][2]

Group 1: WanTai Bio - WanTai Bio announced that its HIV urine self-test kit has received prequalification (PQ) certification from the World Health Organization (WHO), marking it as the first HIV antibody urine self-test kit globally to achieve this status [1] - This certification allows the product to participate in procurement projects by the United Nations and other global multilateral organizations, enhancing the company's international competitiveness [1] - The recognition from WHO is expected to boost investor confidence in the company's research and market potential [1] Group 2: East China Pharmaceutical - East China Pharmaceutical's subsidiary received approval from the National Medical Products Administration (NMPA) for the clinical trial of HDM2005, an antibody-drug conjugate targeting ROR1 for treating diffuse large B-cell lymphoma (DLBCL) [2] - The drug is currently in the fifth dose escalation phase of its clinical trial in China, with no dose-limiting toxicities reported so far [2] - The approval of HDM2005's clinical trial represents a significant advancement in the company's research and development in the oncology field [3] Group 3: GuiChuang TongQiao - GuiChuang TongQiao announced that it will remove the "B" designation from its stock name starting May 9, 2025, indicating that it no longer falls under the category of unprofitable companies [4] - This change reflects the company's achievement of higher operational and performance standards, which is expected to enhance its influence in the capital market and investor recognition [4]

Core Insights - Guichuang Tongqiao Medical Technology Co., Ltd. has received approval from the Hong Kong Stock Exchange to remove the "B" designation from its stock code, marking it as the first 18A high-value consumable medical device company to achieve this milestone in the Hong Kong market [1][2] - The removal of the "B" designation signifies the company's recognition by the capital market for its sustained growth and scalable profitability, enhancing its influence in the capital market [1] - In 2024, the company achieved a revenue of 780 million yuan, representing a year-on-year growth of 48.3%, and net profit exceeded 100 million yuan, marking its first annual profit [1] Revenue and Profitability - The company announced its first cash dividend post-listing, with a total cash dividend of 32.47 million yuan (before tax), while also increasing the maximum amount for its H-share repurchase plan to 650 million HKD [1] - Since its listing in 2021, the company has accelerated its product pipeline and commercialization efforts, establishing 66 product lines, with 47 products approved for market by NMPA [2] - The company has successfully participated in multiple rounds of provincial and national centralized procurement in 2024, with key products winning bids [2] Global Expansion - The company's overseas business has shown rapid growth, achieving revenue of 22.58 million yuan in 2024, with a compound annual growth rate of 87% over the past four years [2] - Currently, 20 products have been commercialized in 24 countries and regions, including Germany, Italy, Argentina, Brazil, and the UAE [2] Leadership Vision - The Chairman and CEO, Dr. Zhao Zhong, emphasized that the successful removal of the "B" designation is a milestone for the company, which will continue to innovate and leverage its competitive advantages in product innovation and operational efficiency [2]